Gustave Roussy is the first leader cancer-research hospital in Europe and ranked among the top 5 best specialized hospitals in the world. It is a centre for high quality patient care, research and teaching. It is highly-known for the treatment of: skin cancers like melanoma, breast cancer, and lung cancer.

There are 457 beds in Institut Gustave Roussy.

During the past decade, Institut Gustave Roussy conducted 653 clinical trials. In the 10-year time frame, 653 clinical trials started and 133 clinical trials were completed, i.e. on average, 20.4% percent of trials that started reached the finish line to date. In the past 5 years, 230 clinical trials started and 83 clinical trials were completed. i.e. 36.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Gustave Roussy" #1 sponsor was "Gustave Roussy, Cancer Campus, Grand Paris" with 165 trials, followed by "UNICANCER" with 95 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 81 trials sponsored, "Centre Leon Berard" with 43 trials sponsored and "Hoffmann-La Roche" with 43 trials sponsored. Other sponsors include 746 different institutions and companies that sponsored additional 245 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Gustave Roussy" #1 collaborator was "National Cancer Institute, France" with 35 trials as a collaborator, "Merck Sharp & Dohme LLC" with 29 trials as a collaborator, "AstraZeneca" with 21 trials as a collaborator, "Bristol-Myers Squibb" with 17 trials as a collaborator and "Gustave Roussy, Cancer Campus, Grand Paris" with 17 trials as a collaborator. Other collaborators include 606 different institutions and companies that were collaborators in the rest 339 trials.

According to Clinical.Site data, the most researched conditions in "Institut Gustave Roussy" are "Breast Cancer" (73 trials), "Prostate Cancer" (28 trials), "Colorectal Cancer" (25 trials), "Ovarian Cancer" (25 trials) and "Melanoma" (23 trials). Many other conditions were trialed in "Institut Gustave Roussy" in a lesser frequency.

Most popular intervention types in "Institut Gustave Roussy" are "Drug" (894 trials), "Other" (135 trials), "Procedure" (127 trials), "Radiation" (103 trials) and "Biological" (81 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (69 trials), "Atezolizumab" (39 trials), "radiation therapy" (35 trials), "Pembrolizumab" (32 trials) and "Carboplatin" (30 trials). Other intervention names were less common.

The vast majority of trials in "Institut Gustave Roussy" are 972 trials for "All" genders, 148 trials for "Female" genders and 58 trials for "Male" genders.

Currently, there are NaN active trials in "Institut Gustave Roussy". 7 are not yet recruiting, 271 are recruiting, 188 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 475 completed trials in Institut Gustave Roussy, 10 suspended trials, and 106 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Gustave Roussy, 257 "Phase 1" clinical trials were conducted, 501 "Phase 2" clinical trials and 330 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 118 trials that are defined as “Not Applicable".

Institut Gustave Roussy has several departments that took part in Clinical trials: "Institut Gustave Roussy; Departement Oncologie Medicale" - 20 trials, "Gustave Roussy Cancer Campus" - 2 trials, "Institut Gustave Roussy; Service Pediatrique" - 5 trials, "Institut Gustave Roussy; Dermatologie" - 5 trials, "Institut Gustave Roussy; Unite D'Hematologie" - 4 trials, "Institut Gustave Roussy; Pathologie Thoracique" - 3 trials